9
H index
8
i10 index
235
Citations
Adrian Towse : Citation Profile
Office of Health Economics | RESEARCH PRODUCTION: 19 Articles 30 Papers 13 Books RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
28 years (1995 - 2023). Relations with other researchers
Works with:
Authors registered in RePEc who have co-authored more than one work in the last five years with Adrian Towse. | Is cited by:
| Cites to:
|
Main data
Where Adrian Towse has published?
| Journals with more than one article published | # docs |
|---|---|
| The European Journal of Health Economics | 6 |
| Health Economics | 3 |
| PharmacoEconomics | 2 |
| International Journal of the Economics of Business | 2 |
| Health Policy | 2 |
| Working Papers Series with more than one paper published | # docs |
|---|---|
| Briefing / Office of Health Economics | 17 |
| Monograph / Office of Health Economics | 14 |
| Occasional Paper / Office of Health Economics | 6 |
| NBER Working Papers / National Bureau of Economic Research, Inc | 2 |
Recent works citing Adrian Towse (2024 and 2023)
| Year | Title of citing document |
|---|---|
| 2023 | A cost-benefit analysis of the medicines patent pool. (2023). Wang, Lucy Xiaolu. In: Economics Bulletin. RePEc:ebl:ecbull:eb-23-00047. Full description at Econpapers || Download paper |
| 2023 | Market diffusion of biosimilars in off-patent biologic drug markets across Europe. (2023). Steiner, Isa Maria ; Bohm, Anna-Katharina ; Stargardt, Tom. In: Health Policy. RePEc:eee:hepoli:v:132:y:2023:i:c:s0168851023001033. Full description at Econpapers || Download paper |
| 2023 | Value assessment of antimicrobials using the STEDI framework – How steady is the outcome?. (2023). Steuten, Lotte ; al Taie, Amer ; Brassel, Simon. In: Health Policy. RePEc:eee:hepoli:v:136:y:2023:i:c:s016885102300177x. Full description at Econpapers || Download paper |
| 2024 | Marginal cost per QALY estimates: What are they good for?. (2024). Cookson, Graham ; Sampson, Chris. In: Health Policy. RePEc:eee:hepoli:v:142:y:2024:i:c:s0168851024000460. Full description at Econpapers || Download paper |
| 2023 | Are ideas being fished out?. (2023). Knott, Anne Marie ; Kluppel, Leonardo. In: Research Policy. RePEc:eee:respol:v:52:y:2023:i:2:s004873332200186x. Full description at Econpapers || Download paper |
| 2024 | Competition, value-based prices and incentives to research personalised drugs. (2024). Levaggi, Rosella. In: Socio-Economic Planning Sciences. RePEc:eee:soceps:v:93:y:2024:i:c:s0038012124000697. Full description at Econpapers || Download paper |
| 2024 | Financial burden of medicines in five Northern European countries: A decommodification perspective. (2024). Vaalavuo, Maria ; Aaltonen, Katri. In: Social Science & Medicine. RePEc:eee:socmed:v:347:y:2024:i:c:s0277953624002430. Full description at Econpapers || Download paper |
| 2023 | . Full description at Econpapers || Download paper |
| 2023 | . Full description at Econpapers || Download paper |
| 2023 | Does private health insurance prevent the onset of critical illness and disability in a universal public insurance system?. (2023). Lee, Dong-Hwa ; Kim, Daehwan. In: The Geneva Papers on Risk and Insurance - Issues and Practice. RePEc:pal:gpprii:v:48:y:2023:i:1:d:10.1057_s41288-021-00251-5. Full description at Econpapers || Download paper |
| 2023 | Can the UK ‘Netflix’ Payment Model Boost the Antibacterial Pipeline?. (2023). Cooper, Sophie ; Glover, David ; Crabb, Nick ; Leonard, Colm ; Perkins, Mark ; Wobbe, Milena ; Bouvy, Jacoline. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:21:y:2023:i:3:d:10.1007_s40258-022-00786-1. Full description at Econpapers || Download paper |
Works by Adrian Towse:
| Year | Title | Type | Cited |
|---|---|---|---|
| In: . [Full Text][Citation analysis] | paper | 1 | |
| 2019 | The Future of Global Health Procurement: Issues around Pricing Transparency In: Working Papers. [Full Text][Citation analysis] | paper | 2 |
| 2017 | Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation In: Health Policy. [Full Text][Citation analysis] | article | 8 |
| 1999 | Is disease management relevant in Europe: some evidence from the United Kingdom In: Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2022 | Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases In: Post-Print. [Citation analysis] | paper | 0 |
| 2023 | Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases.(2023) In: Applied Economics Letters. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 0 | article | |
| 2011 | Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement In: NBER Working Papers. [Full Text][Citation analysis] | paper | 16 |
| 2015 | Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement.(2015) In: Health Economics. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 16 | article | |
| 2012 | Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context In: NBER Working Papers. [Full Text][Citation analysis] | paper | 5 |
| 2014 | What is the Role of HTA for Biosimilars? In: Briefing. [Full Text][Citation analysis] | paper | 1 |
| 2008 | The Market for Biosimilars: Evolution and Policy Options In: Briefing. [Full Text][Citation analysis] | paper | 7 |
| 2006 | Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds In: Briefing. [Full Text][Citation analysis] | paper | 0 |
| 1997 | Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry In: Briefing. [Full Text][Citation analysis] | paper | 2 |
| 1998 | From Efficacy to Cost-Effectiveness In: Briefing. [Full Text][Citation analysis] | paper | 3 |
| 2003 | Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help? In: Briefing. [Full Text][Citation analysis] | paper | 1 |
| 2016 | How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies In: Briefing. [Full Text][Citation analysis] | paper | 1 |
| 2017 | How can HTA meet the needs of health system and government decision makers? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Transferability of HTA In: Briefing. [Full Text][Citation analysis] | paper | 0 |
| 2017 | HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Incentives for New Drugs to Tackle Anti-Microbial Resistance In: Briefing. [Full Text][Citation analysis] | paper | 1 |
| 2017 | Additional Elements of Value for Health Technology Assessment Decisions In: Briefing. [Full Text][Citation analysis] | paper | 4 |
| 2017 | Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward In: Briefing. [Full Text][Citation analysis] | paper | 4 |
| 2019 | Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
| 2019 | Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
| 2012 | The R&D Cost of a New Medicine In: Monograph. [Full Text][Citation analysis] | book | 21 |
| 2011 | New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options In: Monograph. [Full Text][Citation analysis] | book | 3 |
| 2010 | Biosimilars: How Much Entry and Price Competition Will Result? In: Monograph. [Full Text][Citation analysis] | book | 3 |
| 2008 | The Ideas and Influence of Alan Williams: Be Reasonable – Do It My Way In: Monograph. [Full Text][Citation analysis] | book | 2 |
| 2006 | Economic Post-Launch Studies: Matching the Desirable with the Feasible In: Monograph. [Full Text][Citation analysis] | book | 1 |
| 1995 | Financing Health Care in the UK: A Discussion of NERA’s Prototype Model to Replace the NHS In: Monograph. [Full Text][Citation analysis] | book | 2 |
| 1995 | Industrial Policy and the Pharmaceutical Industry In: Monograph. [Full Text][Citation analysis] | book | 1 |
| 1995 | Value of the Pharmaceutical Industry to the UK Economy In: Monograph. [Full Text][Citation analysis] | book | 0 |
| 1997 | Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada? In: Monograph. [Full Text][Citation analysis] | book | 2 |
| 1999 | Disease Management, the NHS and the Pharmaceutical Industry In: Monograph. [Full Text][Citation analysis] | book | 0 |
| 2002 | Cost-Effectiveness Thresholds: Economic and ethical issues In: Monograph. [Full Text][Citation analysis] | book | 21 |
| 2002 | Influencing Prescribing in a Primary Care Led NHS In: Monograph. [Full Text][Citation analysis] | book | 0 |
| 2002 | Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty In: Monograph. [Full Text][Citation analysis] | book | 4 |
| 2020 | How Should the World Pay for a COVID-19 Vaccine? In: Monograph. [Full Text][Citation analysis] | paper | 2 |
| 2013 | Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold In: Occasional Paper. [Full Text][Citation analysis] | paper | 12 |
| 2012 | The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation? In: Occasional Paper. [Full Text][Citation analysis] | paper | 3 |
| 2011 | Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? In: Occasional Paper. [Full Text][Citation analysis] | paper | 2 |
| 2010 | New Drugs to Tackle Antimicrobial Resistance: EU Policy Options In: Occasional Paper. [Citation analysis] | paper | 1 |
| 2014 | Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies? In: Occasional Paper. [Full Text][Citation analysis] | paper | 0 |
| 2015 | International Decision Support Initiative (iDSI): Mapping of priority-setting in health in 17 low and middle countries across Asia, Latin America, and Africa In: Occasional Paper. [Full Text][Citation analysis] | paper | 0 |
| 2015 | Multi-indication Pricing: Pros, Cons and Applicability to the UK In: Seminar Briefing. [Full Text][Citation analysis] | paper | 5 |
| 2016 | Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria In: Oxford Review of Economic Policy. [Full Text][Citation analysis] | article | 0 |
| 2021 | Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al. In: Medical Decision Making. [Full Text][Citation analysis] | article | 1 |
| 2022 | Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 1 |
| 2012 | Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 16 |
| 2014 | Orphan drugs policies: a suitable case for treatment In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 10 |
| 2019 | Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 13 |
| 2019 | Is rate of return pricing a useful approach when value-based pricing is not appropriate? In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 2 |
| 2004 | Genetic screening, health care and the insurance industry In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 3 |
| 2006 | The desirability and feasibility of economic studies of drugs post-launch In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 1 |
| 2013 | Operationalizing Value-Based Pricing of Medicines In: PharmacoEconomics. [Full Text][Citation analysis] | article | 14 |
| 2016 | Biosimilars: How Can Payers Get Long-Term Savings? In: PharmacoEconomics. [Full Text][Citation analysis] | article | 9 |
| 2011 | Incentives for R&D for New Antimicrobial Drugs In: International Journal of the Economics of Business. [Full Text][Citation analysis] | article | 0 |
| 2015 | European Union Pharmaceutical Markets: A Case for Differential Pricing? In: International Journal of the Economics of Business. [Full Text][Citation analysis] | article | 9 |
| 2007 | If it aint broke, dont price fix it: the OFT and the PPRS In: Health Economics. [Full Text][Citation analysis] | article | 7 |
| 1999 | Medical negligence and the NHS: an economic analysis In: Health Economics. [Full Text][Citation analysis] | article | 8 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated November, 3 2024. Contact: CitEc Team